Number of words in Abstract: 246 prevented the increase in Cyp1a1 activity, indicating that the induction of enzyme activity by tBHQ is dependent on de novo protein synthesis. In addition, the AHR antagonist, resveratrol, inhibited the increase in Cyp1a1 activity by tBHQ. Gel electrophoretic mobility shift assays showed that tBHQ causes activation or transformation of the AHR in nuclear extracts, indicating that AHR-dependent mechanisms contributed to the Cyp1a1 induction. Similar to murine Hepa 1c1c7 cells, tBHQ caused a concentration-dependent increase in CYP1A1 at the mRNA and activity levels in human HepG2 cells. This is the first demonstration that the phenolic antioxidant, tBHQ, can directly induce Cyp1a1 gene expression in an AHR-dependent manner and may represent a novel mechanism by which tBHQ promotes carcinogenicity.
DMD #2253 Introduction
The aryl hydrocarbon receptor (AHR) is a ligand-activated basic helix-loop-helix transcription factor (bHLH) that controls the expression of different genes whose functions are linked to the metabolism of dietary constituents, drugs, and potentially hazardous agents such as environmental contaminants (Burbach et al., 1992; Ema et al., 1992) . The AHR exists as cytoplasmic aggregates bound to two 90-kDa heat-shock proteins (HSP90), the cochaperone p23 and a 43-kDa protein termed hepatitis B virus X-associated protein (Ma and Whitlock, 1996; Carver and Bradfield, 1997; Meyer et al., 1998) . Upon ligand binding, the AHR dissociates from HSP90 and the ligand-receptor complex translocates to the nucleus. Then, the activated AHR dimerizes with the AHR nuclear translocator protein (ARNT), and binds to a class of promoter DNA sequences called xenobiotic responsive elements (XRE) of the target genes to activate their transcription (Nebert et al., 1993; Whitlock, 1999) . The AHR-regulated genes consist of four phase I enzymes, cytochrome P450 1A1 (CYP1A1), CYP1A2, CYP1B1 and CYP2S1 and several Phase II enzymes that are involved in the metabolism of xenobiotics and endogenous compounds (Nebert et al., 2000; Rivera et al., 2002) .
Among the AHR-regulated genes, CYP1A1 is the most capable in producing polar, toxic or even carcinogenic metabolites from various AHR ligands including aromatic and halogenated hydrocarbons (Schrenk, 1998) . These metabolites have been shown to be involved in the mediation of a broad range of distinct toxic responses such as immune suppression, endocrine disruption, birth defects, and carcinogenesis (Poland and Knuston, 1982) .
tert-butylhydroquinone (tBHQ) is a major metabolite of 3-tert-butyl-hydroxyanisole (BHA) in vivo in dogs, rats, and humans (Nakamura et al., 2003) . BHA has been widely used for many years as an antioxidant to preserve and stabilize the freshness, nutritive value, flavour and DMD #2253 colour of foods and animal food products (Williams et al., 1999; Li et al., 2002) . Both tBHQ and BHA have received a lot of attention due to their ability to induce Phase II detoxification enzymes, including glutathione S-transferase and NADPH: quinone oxidoreductase and thus their potential role in cancer prevention (Li et al., 2002) . In contrast to the beneficial effects of BHA, a number of studies have shown that chronic exposure to high concentrations of BHA in diet induces neoplastic lesions in the forestomach, urinary bladder and esophagus of rats, mice, hamsters, and pigs (Li et al., 2002) .
Although the carcinogenicity of BHA in animals, particularly at high concentrations, has been well documented, the relevance of these results to the low exposure of humans to BHA has been questioned (Li et al., 2002) . Recently, a study on the carcinogenicity of BHA, at low concentrations, alone or in combination with other phenolic chemicals, including caffeic acid, sesamol, 4-methoxyphenol and catechol in rats has shown that the above phenolic compounds exerted synergistic effects on rat forestomach carcinogenesis (Li et al., 2002) . Assessing the risk from human consumption of BHA and tBHQ is complicated by the fact that the precise mechanisms of their carcinogenicity are not well understood. The metabolic formation of tBHQ has been suggested to, at least in part; contribute to the carcinogenicity effect of BHA.
In an attempt to investigate the mechanisms by which tBHQ induces toxicity or carcinogenicity, we examined the effect of tBHQ on Cyp1a1 mRNA, protein and enzyme activity in murine hepatoma Hepa 1c1c7 cells. The involvement of the AHR-dependent signalling pathway was also investigated by using an AHR antagonist and gel electrophoretic mobility shift assay (EMSA). Here, we provide the first direct evidence for an AHR-dependent induction of Cyp1a1 gene expression and enzyme activity by the tBHQ, which has a single unsaturated phenolic ring (Fig. 1) .
DMD #2253
Eagle's medium (DMEM), without phenol red, supplemented with 10% fetal bovine serum (FBS), 20 µM L-glutamine, 50 µg/ml gentamycin sulfate, 100 IU/ml penicillin, 10 µg/ml streptomycin and 25 ng/ml amphotericin B, 0.1 mM non-essential amino acids, and vitamin supplement solution. Cells were grown in 75-cm 2 tissue culture flasks at 37°C in a 5% CO 2 humidified incubator.
tBHQ and resveratrol were dissolved in dimethylsulfoxide (DMSO Effect of tBHQ on Cell Viability. The effect of tBHQ on cell viability was determined using the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay as described previously (Vakharia et al., 2001) . The assay measures the conversion of MTT to formazan crystal by enzymes in the mitochondria of metabolically active cells. Briefly, Hepa 1c1c7 cells were seeded into 96-well microtiter cell culture plates and incubated for 24 h at 37°C in a 5%
CO 2 humidified incubator. Cells were treated with various concentrations of tBHQ (0, 1, 10, 50, 100, and 500 µM). After 24 h incubation, the medium was removed and replaced with cell
culture medium containing 1.2 mM of MTT dissolved in PBS (pH 7.4). After 2 h of incubation, the formed crystals were dissolved with isopropanol. The intensity of the color in each well was measured at a wavelength of 550 nm using the BIO-TEK EL 312e microplate reader.
Determination of Cyp1a1 Activity. The Cyp1a1-dependent 7-ethoxyreorufin O-deethylase (EROD) activity was performed on intact, living cells as described previously (Elbekai and ElKadi, 2004; Korashy and El-Kadi, 2004) . Enzymatic activity was normalized for cellular protein content which was determined using a modified fluorescent assay (Elbekai and El-Kadi, 2004; Korashy and El-Kadi, 2004) .
RNA Extraction and Northern Blot Analysis.
After incubation with the test compounds for the specified time periods, total cellular RNA was isolated using TRIzol reagent, according to manufacturer's instructions (Invitrogen), and quantified by measuring the absorbance at 260 nm.
Northern blot analysis of total RNA was performed as described elsewhere (Sambrook et al., 1989) . Briefly, aliquots of 20 µ g of RNA were separated in a denaturing (2.2 M formaldehyde) agarose (1.1%) gel and transferred to Hybond-N nylon membranes. The RNA was cross-linked to the membranes using the UV Stratalinker 2400, followed by baking at 65°C for 2 h. Western Blot Analysis. Cells treated with tBHQ for 24 h were collected in lysis buffer containing 50 mM HEPES, 0.5 M sodium chloride, 1.5 mM magnesium chloride, 1 mM EDTA, 10% (v/v) glycerol, 1% Triton X-100, and 5µl/ml of protease inhibitor cocktail. The cytosolic fractions were obtained by incubating the cell lysates on ice for 1 h, with intermittent vortexing every 10 min, followed by centrifugation at 12,000 g for 10 min at 4 ○ C. Proteins (100 µg) were resolved by denaturing electrophoresis, as described previously (Sambrook et al., 1989; Elbekai and El-Kadi, 2004; Korashy and El-Kadi, 2004) . Briefly, the cytosol supernatants were dissolved in 1x sample buffer, boiled for 5 min, separated by 7.5% SDS-PAGE bis-acrylamide gel electrophoresis and electrophoretically transferred to a nitrocellulose membrane. Protein blots were blocked for 24 h at 4 Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Analysis of mRNA. RT was performed using Murine Leukemia Virus reverse transcriptase (Invitrogen) as described previously (Li et al., 1998) . Purified total RNA (2.5 µg) was used in each reaction. PCR was performed using AmpliTAQ DNA Polymerase (Perkin-Elmer) according to the manufacturer's instructions. RT reaction mixture (2.5 µl) was used for each PCR. Agarose gel electrophoresis was used to separate PCR-amplified products. Ethidium bromide was added to the gel before solidification. PCR products were visualized under a UV transluminator and digitally recorded.
Band intensity was quantitated using ImageQuant software (Amersham-Pharmacia). Primer sequences used were: CYP1A1 forward, 5'-GACCTGAATGAGAAGTTCTACAGC-3'; reverse, 5'-CGGAAGGTCTCCAGGATGAAG-3' and β -actin forward, 5'-CTACAATGAGCTGCGTGTGG-3'; reverse, 5'-TAGCTCTTCTCCAGGGAGGA-3' as described previously (Li et al., 1998; Roblin et al., 2004) .
Nuclear Extracts and EMSA. Nuclear extracts were prepared as described previously (Rogers et al., 2002) . A complementary pair of synthetic oligonucleotides containing the XRE3 binding site for the transformed AHR/ARNT complex (5'-GATCTGGCTCTTCTCACGCAACTCCG-3'
and 5'-GATCCGGAGTTGCGTGAGAAGAGCCA-3') were synthesized, purified, annealed, and radiolabeled with [γ 32 P]ATP as described previously (Denison et al., 1988) . For EMSA 
Results
Effect of tBHQ on Cell Viability. To determine the optimal concentrations to use in our studies, tBHQ was tested for potential cytotoxicity in Hepa 1c1c7 cells. Fig. 2 shows that tBHQ at concentrations of 1-100 µM did not affect cell viability. However, 500 µM, the highest concentration tested, caused a 59% decrease in the cell viability. Therefore, all subsequent studies were conducted using concentrations of 1-100 µM.
Increase in Cyp1a1 Expression after tBHQ Treatment. Northern blot analysis was performed to examine the time-dependent effect of tBHQ on Cyp1a1 mRNA. At a concentration of 100 µM, tBHQ caused a time-dependent increase in Cyp1a1 mRNA level (Fig. 3) . The onset of induction was achieved only 3 h after the addition of tBHQ but Cyp1a1 mRNA levels remained elevated for at least 12 h post tBHQ treatment.
To examine the concentration-dependent effect of tBHQ on Cyp1a1 mRNA, the cells were treated with various concentrations of tBHQ (1-100 µM). Fig. 4 illustrates that tBHQ caused a concentration-dependent increase in Cyp1a1 mRNA levels already apparent at a concentration of 10 µM, whereas maximum induction was obtained at about 100 µM.
To assess whether the increase in Cyp1a1 mRNA level was accompanied by an increase in protein expression, quantitative measurement of Cyp1a1 protein using Western blot analysis was carried out. Our results clearly show that only the highest concentrations tested, 50 and 100 µM of tBHQ caused significant induction in Cyp1a1 protein levels (Fig. 5) .
Furthermore, to assess the functional implication of exposure to tBHQ, Cyp1a1-dependent EROD activity was also measured in Hepa 1c1c7 cells (Fig. 6 ). Significant increase in This article has not been copyedited and formatted. The final version may differ from this version. EROD activity was measured at 10, 50 and 100 µM of tBHQ (1.6, 3.3 and 3.0 fold increase compared to control, respectively) which correlates with the mRNA data.
Effect of tBHQ on CYP1A1 in HepG2 cells. To examine whether tBHQ causes similar effect in human cells, human hepatoma HepG2 cells were treated with various concentrations of tBHQ (0-100 µM). Similar to the results obtained with Hepa 1c1c7 cells, tBHQ caused a concentrationdependent increase in CYP1A1 at the mRNA and activity levels in HepG2 cells ( Fig. 7A and B) .
However, at the highest concentration tested, 100 µM, the induction in CYP1A1 mRNA and activity was less than that obtained with the 50 µM concentration, probably due to reduced cell viability (about 25% decrease in the cell viability, data not shown).
Effect of RNA and Protein Synthesis Inhibitors. To determine whether the increase in Cyp1a1
expression in response to tBHQ was a result of de novo RNA synthesis or a post-transcriptional effect, Hepa 1c1c7 cells were co-treated with the RNA polymerase inhibitor Act-D. Treatment with 5 µg/ml Act-D 2 h before exposure to 100 µM tBHQ completely abolished the increase in Cyp1a1 mRNA (Fig. 8A) . Act-D also completely blocked the increase in Cyp1a1-dependent EROD activity in response to 100 µM tBHQ (Fig. 8B) .
We also determined whether the increased cyp1a1 mRNA levels due to tBHQ exposure was dependent on the action of a highly labile or de novo synthesized protein. Hepa 1c1c7 cells were treated with the protein synthesis inhibitor, CHX (1 µg/ml) in the presence or absence of tBHQ (100 µM) for 6 h. Our results clearly demonstrated that in the absence of tBHQ, CHX alone significantly increased the Cyp1a1 mRNA level. In addition, co-treatment of cells with CHX and tBHQ superinduced the increase in Cyp1a1 mRNA levels by CHX (Fig. 9A) . With 
Discussion
To date, numerous chemicals have been identified as AHR ligands .
Most of them, the "classical" ligands, including polycyclic aromatic hydrocarbons (PAHs) and halogenated aryl hydrocarbons share the structural features of being planar, aromatic and hydrophobic (Denison and Nagy, 2003) . Recently, a relatively large number of AHR ligands whose structures and physiochemical characteristics differ from classical ligands have been identified (Denison and Nagy, 2003) . The majority of these "non-classical" AHR ligands have a low affinity to the AHR and are relatively weak inducers of Cyp1a1, compared to TCDD. A wide range of structural diversity in AHR ligands indicates that a greater spectrum of chemicals can interact with and activate this receptor than previously thought (Denison and Nagy, 2003) .
Here, our data provide strong evidence that tBHQ, which has a single unsaturated phenolic ring, is a weak ligand of AHR compared to TCDD, and can directly induce Cyp1a1 gene expression and enzymatic activity in an AHR-dependent manner.
Humans consume appreciable amounts of phenolic antioxidants including BHA and its active metabolite, tBHQ, as food additives from dietary sources (Ma and Kinneer, 2002) . tBHQ has been found to be a prototype inducer of a non receptor signalling pathway which selectively induces Phase II enzymes in an AHR-independent manner and exhibits anticarcinogenic effects (Li et al., 2002; Munzel et al., 2003) . Induction of Phase II enzymes by tBHQ requires an antioxidant responsive element (ARE) located in the enhancers of genes and is mediated through an Nrf2-dependent signal transduction (Ma and Kinneer, 2002) . Nrf2 is a redox-sensitive member of the CNC bzip (cap 'n' collar basic leucine zipper) family of transcription factors that forms a cytoplasmic complex with Keap1 (Ma and Kinneer, 2002) . In the presence of tBHQ, Nrf2 dissociates from Keap1 and translocates into the nucleus, followed by dimerization with This article has not been copyedited and formatted. The final version may differ from this version. (Ma and Kinneer, 2002) .
On the other hand, evidence is being provided that the bioactivation of tBHQ through a Cu(II)/Cu(I) redox cycle mechanism results in the formation of 2-tert-butyl(1,4)paraquinone (tBQ), semiquinone anion radical and reactive oxygen species (ROS). The ROS may be involved in oxidative DNA damage and hence contribute to the carcinogenicity of BHA (Li et al., 2002) .
However, other mechanisms may be involved.
Despite the extensive interest in the effect of tBHQ on human health, little is known about the physiologically relevant concentration attainable in human plasma and tissue, but it has been estimated that the daily consumption of tBHQ may reach 28-42 mg/day (European Food and Safety Authority, 2004) . Moreover, it has been reported that when a single dose of 125 mg tBHQ was given orally to adult male volunteers, the plasma level of tBHQ was 31-37 mg/l which is equivalent to 187-223 µM (European Food and Safety Authority, 2004) . Considering the daily consumption of tBHQ is about 28-42 mg we estimate the plasma concentration will range from 50-75 µM.
To further understand the mechanisms involved in BHA carcinogenesis, we hypothesized that tBHQ acts as an AHR ligand and induce Cyp1a1. The reason is that the conversion of AHR ligands into electrophilic compounds by Cyp1a1, results in the formation of covalent adducts which can react directly with intracellular nucleophiles, including DNA, and initiate the cancer process (Spink et al., 2002) . To test this hypothesis, we investigated the effect of tBHQ on µM or 500 µM of tBHQ had no effect on Cyp1a1 at the mRNA or activity levels (Liu et al., 1994; Vasiliou et al., 1995; Lamb and Franklin, 2002) . We have found that tBHQ does not induce Cyp1a1 expression at 500 µM due to increased cytotoxicity at that concentration (Fig. 2) .
Other aspects of our data are also worth noting. The time course study for Cyp1a1 mRNA induction indicates that the increase in response to tBHQ was somewhat delayed with the increase in Cyp1a1 mRNA levels being clearly achieved 3 h post tBHQ treatment. However, the onset of Cyp1a1 mRNA increase was rapid and readily apparent by 1 h for TCDD (data not shown). In addition, induction of EROD activity 24 h after treatment with 100 µM tBHQ was only 40% of that observed for TCDD (data not shown). Taken together, these data suggest that tBHQ induces Cyp1a1, albeit with lower affinity than TCDD.
Further evidence for the involvement of the AHR comes from the result of the EMSA.
Presence of a nuclear AHR complex is dependent on ligand binding by the cytosolic receptor, transformation, nuclear accumulation, and DNA binding, similar to that observed with other AHR ligands such as TCDD, but also support a role for the AHR in the induction of Cyp1a1. To support our conclusion, the EROD activity induced by tBHQ was significantly prevented by the AHR antagonist, resveratrol, suggesting a direct contribution of an AHR-dependent mechanism.
We also attribute the changes in mRNA expression to a direct effect on transcription.
Inhibition of tBHQ-mediated induction of Cyp1a1 mRNA in Hepa 1c1c7 cells treated with the RNA synthesis inhibitor Act-D demonstrates a requirement for de novo mRNA synthesis, consistent with increased gene transcription mediated by the ligand-bound AHR complex. It has been previously reported that in Hepa 1c1c7 cells, superinduction of Cyp1a1 mRNA is a transcriptional event involving a liganded AHR (Isreal et al., 1985) and is considered to reflect the existence of a labile repressor protein that inhibits the response of the receptor-enhancer system through protein-protein interactions (Lusska et al., 1992 ). Our results demonstrate that CHX alone significantly increased the Cyp1a1 mRNA which was superinduced in the presence of CHX and tBHQ, indicating that the superinduction requires the activation of AHR by an agonist. Therefore, tBHQ increases the Cyp1a1 gene expression through an AHR-dependent mechanism. The Cyp1a1-mediated induction by CHX alone, in the absence of an additional exogenous inducing agent, has been noted in various cell types (Giachelli et al., 1991) . In addition, inhibition of tBHQ-mediated induction of Cyp1a1 activity by CHX indicates that de novo Cyp1a1 protein synthesis is required.
Taken all together, the results provided here present us with the first evidence that tBHQ, a phenolic antioxidant; can directly modulate the expression of Cyp1a1 through an AHRdependent pathway by acting as an AHR ligand. In addition, induction of Cyp1a1 by tBHQ may be directly or indirectly involved in BHA carcinogenesis.
This article has not been copyedited and formatted. The final version may differ from this version. Cells were treated with vehicle or tBHQ (0, 1, 10, 50, and 100 µM) for 6 and 24 h for mRNA and EROD activity, respectively. A, Cyp1a1 mRNA was determined using the RT-PCR method as described under Materials and Methods. β-Actin was included as internal control. This experiment was repeated on three occasions but only one representative result is shown. B, Cyp1a1-dependent EROD activity was determined as described under Materials and Methods. 
